Table 3 Toxicity
ACE ( N =137), no. of patients (%) | PE ( N =140), no. of patients (%) | |||
|---|---|---|---|---|
Toxicity | Grades 1 and 2 | Grades 3 and 4 | Grades 1 and 2 | Grades 3 and 4 |
Haematologic adverse events | ||||
Anaemia | 88 (64) | 38 (28) | 96 (69) | 27 (19) |
Neutropenia | 3 (2) | 125 (91) | 47 (34) | 82 (59) |
Thrombocytopenia | 36 (26) | 77 (56) | 39 (28) | 69 (49) |
Non-haematologic adverse events | ||||
Infection | 13 (9) | 100 (73) | 24 (18) | 40 (39) |
Nausea | 65 (47) | 06 (4) | 75 (55) | 13 (9) |
Vomiting | 41 (30) | 3 (2) | 52 (38) | 8 (6) |
Constipation | 37 (27) | 2 (1) | 55 (41) | 4 (3) |
Oral mucositis | 63 (46) | 9 (7) | 50 (37) | 2 (1) |
Lethargy | 80 (59) | 13 (9) | 96 (70) | 14 (10) |
Anorexia | 68 (50) | 8 (6) | 76 (56) | 5 (4) |
Alopecia (grades 1–3) | 42 (31) | 52 (38) | 65 (48) | 72 (51) |
Hoarse voice | 35 (26) | 2 (1) | 27 (20) | 6 (4) |
Neuropathy | 16 (12) | 0 | 29 (21) | 1 (1) |
Cough | 84 (61) | 1 (1) | 84 (62) | 4 (3) |
N =137 (%) | N =136 (%) | P -value | ||
Intravenous/oral antibiotics during all cycles | ||||
No. of patients | None | 17 (12) | 67 (49) | |
Oral only | 3 (2) | 17 (13) | <0.005 | |
Intravenous only | 52 (38) | 21 (16) | ||
Intravenous+oral | 60 (44) | 29 (21) | ||
NK | 5 (4) | 2 (1) | ||
No. of cycles | Affected/ | 243/578 | 76/685 | <0.005 |
possible (%) | (42) | (11) | ||
No. of days | Affected/ | 1390/12138 | 360/14385 | <0.005 |
possible (%) | (11) | (3) | ||
